The nation of Zimbabwe has turned down a major American health deal valued at 367 million US dollars (£272m) spanning five years over Washington's request for sensitive biological samples.
This rejection came to light after a internal memorandum dated December was leaked, indicating that President Emmerson Mnangagwa felt the deal was "lopsided".
A government spokesperson later stated that the US was seeking genetic material for scientific study and commercial purposes while was not willing to share the benefits from any future treatments.
"We are forced to start the difficult and regrettable process of winding down our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had donated over $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged more dialogue to find a deal suitable to all parties so the nation's critical HIV programme can continue.
Broader Background
Zimbabwe's decision follows a comparable case in neighbouring Kenya, where a high court suspended a similar deal with the US after concerns were raised about the safety of Kenyans' medical information.
After returning to office recently, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
The agency had managed assistance for the American government, but Trump stated its spending was "inefficient" and his administration was seeking direct bilateral agreements to enhance openness and responsibility.
Based on statements, 16 nations in Africa have to date agreed to similar agreements, constituting more than $18.3bn in new funding.
Details of the Rejected Agreement
This assistance for Zimbabwe was intended to gone towards "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership could have provided immense advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently on antiretroviral therapy via American-funded initiatives," the Ambassador added.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"Zimbabwe was being asked to provide its biological resources and data over an extended period, with no corresponding guarantee of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," his statement read.
"Effectively, our nation would provide the raw materials for medical research without any assurance that the end products would be available to our citizens should a new health crisis arise."
Sovereignty and International Frameworks
Mangwana further said that the American exit from the global health body and its pursuit of one-on-one health agreements were disrupting frameworks previously established through the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme designed to manage future global health emergencies.
"This mechanism is designed to ensure that when a country provides its information, the benefits – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the capability to develop them."
The government's concerns over the US deal "are not meant as hostility towards the US," he added.
"We welcome further discussions with our American counterparts on how subsequent collaboration might be arranged in a manner that honours the independence and dignity of both nations."
Medical Community Response
Medical experts expressed it recognised the government's concerns, but suggested that talks must proceed considering a large portion of the nation's HIV programmes were funded by foreign aid.
"If specific concerns arise, such as those involving data governance or agreement terms, these can frequently be resolved via detailed discussion and mutually agreed protections," the group said.
This impasse highlights the complex debate between accepting much-needed international aid and safeguarding national sovereignty in an ever more data-driven world.